Metabolic and renal outcomes in cardiac surgery patients receiving SGLT2 inhibitors
- Conditions
- Cardiac surgery associated acute kidney injury
- Registration Number
- NL-OMON26563
- Lead Sponsor
- Amsterdam UMC location AMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
•18 to 90 years old (inclusive)
•Undergoing elective cardiac surgery with cardio-pulmonary bypass.
•Providing informed consent
Exclusion Criteria
•Current treatment with SGLT2 inhibitors.
•Diabetes Mellitus Type 1
•BMI<25 for people with type 2 diabetes
•Reduced renal function at baseline with eGFR < 30 ml/min.
•Systolic blood pressure < 100 mmHg at time of inclusion.
•Emergency surgery, defined as in need of surgery for medical reasons < 7 days, i.e. S1-4” according to the Amsterdam UMC classification.
•Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods.
•Known or suspected allergy to trial products or other drugs in the same class.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eutrophil gelatinase-associated lipocalin (NGAL) concentration in plasma. Measured on morning of postoperative day 2, between 8:00 and 12:00.
- Secondary Outcome Measures
Name Time Method